文献速递骨软组织肉瘤与黑色素瘤

III期BRAF V600突变黑色素瘤辅助治疗真实世界数据的比较——系统文献研究结果

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.
PubMed 文献 · Eur J Cancer · 2024-12-13

本研究系统检索真实世界数据,比较III期BRAF V600突变黑色素瘤辅助靶向治疗(TT)与免疫检查点抑制剂(ICI)的疗效;共纳入9篇文献、3625例患者;TT在6、12、24、36个月的无复归生存(RFS)优于ICI,无远处转移生存(DMFS)呈类似趋势,总生存未见明显差异;作者认为辅助TT可能与更好的RFS和DMFS相关。

要点

  • III期BRAF V600突变黑色素瘤辅助治疗缺乏头对头比较研究,最佳方案尚不明确。
  • 真实世界数据中,TT在6、12、24、36个月RFS优于ICI,DMFS呈类似趋势。
  • 总生存方面TT与ICI未见明显差异;纳入9篇文献共3625例患者。

核心结论

  • 真实世界数据提示,在III期BRAF V600突变黑色素瘤中,与ICI相比,辅助TT可能与更好的RFS和DMFS相关。

研究设计与样本

  • 系统文献研究:系统检索III期黑色素瘤辅助治疗的真实世界数据,纳入9篇文献、共3625例患者;使用Digitizelt软件绘制TT与ICI的Kaplan-Meier曲线。

主要发现

  • TT在6、12、24、36个月的无复归生存(RFS)优于ICI。
  • 无远处转移生存(DMFS)呈与RFS类似的趋势,总生存未见明显差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies. METHODS: We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software. RESULTS: Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival. CONCLUSION: Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Amaral T, Nanz L, Higuita LMS, et al. A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research. Eur J Cancer. 2024. PMID: 39673834. doi:10.1016/j.ejca.2024.115160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。